Coleman RL, Spirtos NM, Enserro D, et al. – In this phase 3 study, researchers assessed secondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube (“ovarian”) cancer. Individuals with recurrent ovarian cancer who had received one former therapy, had an interval during which no platinum-based chemotherapy was used (platinum-free interval) of 6 months or more, and had investigator-determined resectable disease (to no macroscopic residual disease) were randomized to undergo secondary surgical cytoreduction and then receive platinum-based chemotherapy or to receive platinum-based chemotherapy alone. Overall, compared with chemotherapy alone, secondary surgical cytoreduction followed by chemotherapy did not lead to longer overall survival.